



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Pemetrexed in Advanced or Metastatic  
Non-Small Cell Lung Cancer (NSCLC)**

**Approved Use:**

**Pemetrexed:**

1. In combination with cisplatin **as a first line treatment option** in patients with advanced or metastatic NSCLC with non-squamous histology who have an ECOG performance status of 0-2.
2. As a **single agent second line treatment option** in patients with advanced or metastatic NSCLC with non-squamous histology who have an ECOG performance status of 0-2 after failure of only one prior line of therapy.
3. As a **single agent maintenance treatment option** in patients with advanced or metastatic NSCLC with non-squamous histology immediately following a non-pemetrexed containing first line platinum doublet who have an ECOG performance status of 0-2 and have achieved clinical benefit (tumor response or stable disease) from first line therapy.

In any one patient, only **one** of these options may be used during the course of therapy for the treatment of advanced or metastatic NSCLC.

- This policy recommendation represents a **new guideline document** as well as an **update** of the existing restriction of pemetrexed to include first line, second line (update) and maintenance therapy for advanced or metastatic NSCLC patients.